Neurochemistry

Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign

Retrieved on: 
Tuesday, June 22, 2021
Psychoactive drugs, Neurochemistry, Branches of biology, Drinking culture, Alcohol abuse, Substance dependence, Alkermes, CC Sabathia, ALKS, Psychiatric diagnosis, Alcohol dependence, Alcohol

DUBLIN, June 22, 2021 /PRNewswire/ -- Alkermes, Inc. , a subsidiary of Alkermes plc(Nasdaq: ALKS), today announced former professional baseball player and World Series champion, CC Sabathia, as a spokesperson for the company's My Relationship with Alcohol campaign, which is designed to help raise awareness about the disease of alcohol dependence and encourage people who are rethinking their relationship with alcohol to reach out to their healthcare provider.

Key Points: 
  • DUBLIN, June 22, 2021 /PRNewswire/ -- Alkermes, Inc. , a subsidiary of Alkermes plc(Nasdaq: ALKS), today announced former professional baseball player and World Series champion, CC Sabathia, as a spokesperson for the company's My Relationship with Alcohol campaign, which is designed to help raise awareness about the disease of alcohol dependence and encourage people who are rethinking their relationship with alcohol to reach out to their healthcare provider.
  • CC Sabathia has been outspoken about his own alcohol dependence recovery journey in an effort to inspire others who may be struggling with the disease to seek help.
  • "I battled with my drinking for years before making the decision to seek professional help, so I'm looking forward to being part of this campaign to help people rethink their relationship with alcohol," said CC Sabathia.
  • Alcohol dependenceis a chronic disease in which a person craves drinks that contain alcohol and is unable to control their drinking.

Your CBD Store Unveils New "BEYOND by SUNMED" Line, Using Innovative Process to Create Unprecedented Fuller Spectrum Experience

Retrieved on: 
Friday, June 18, 2021
Euphoriants, Entheogens, Psychoactive drugs, Drugs, Appetite stimulants, Cannabis, Cannabinoid, Tetrahydrocannabinol, Neurochemistry

"BEYOND uses 400% more minor cannabinoids rather than using CBD as an isolate, achieving maximum benefits for CBD users seeking a heightened experience.

Key Points: 
  • "BEYOND uses 400% more minor cannabinoids rather than using CBD as an isolate, achieving maximum benefits for CBD users seeking a heightened experience.
  • The BEYOND line features more CBG, CBC, CBN and THC-V among other beneficial compounds to create a cutting-edge fuller spectrum.
  • Since its launch, Your CBD Store has expanded to more than 600 affiliate stores, 200 of which are franchise locations.
  • Its parent company, Sunflora Inc., produces quality products for health and wellness, skincare, and pets.

Ketamine One Closes Previously Announced Acquisition of Integrated Rehab and Performance

Retrieved on: 
Tuesday, June 15, 2021
Psychoactive drugs, Drugs, Neurochemistry, Arylcyclohexylamines, Antidepressants, Chloroarenes, Nicotinic antagonists, General anesthetics, Ketamine

VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (Ketamine One or the Company) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has closed its previously announced acquisition (the Acquisition) of Integrated Rehab and Performance Ltd. (IRP).

Key Points: 
  • VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (Ketamine One or the Company) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that it has closed its previously announced acquisition (the Acquisition) of Integrated Rehab and Performance Ltd. (IRP).
  • As consideration for the Transaction, Ketamine One issued 602,410 common shares of the Company (the Consideration Shares) at a price per common share of $1.66.
  • Currently, Ketamine One has a network of 15 clinics across North America, with plans to further consolidate the highly fragmented industry.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Dr. Jeffrey Kamlet Internationally Recognized Expert on Cardiac Safety in Ibogaine Treatment Joins Ehave as Chief Medical Officer

Retrieved on: 
Tuesday, June 15, 2021
Psychoactive drugs, Drugs, Neurochemistry, Entheogens, NMDA receptor antagonists, Nicotinic antagonists, Ibogaine, Tryptamines, Tabernanthe iboga, Ketamine

Ketamine treatments on anxiety, depression and PTSD using brain mapping technology, stated Ben Kaplan, CEO of Ehave.

Key Points: 
  • Ketamine treatments on anxiety, depression and PTSD using brain mapping technology, stated Ben Kaplan, CEO of Ehave.
  • Dr. Jeffrey Kamlet, M.D, FASAM, DABAM is recognized as the worlds expert on cardiac safety in ibogaine treatment.
  • Dr. Kamlet served as the Global Ibogaine Therapy Alliance's Chief Medical Advisor, as well as Editor in Chief on the Global Ibogaine Therapy Alliance's Clinical Guidelines for Ibogaine-Assisted Detoxification.
  • Additionally, he has worked as an Associate Director and Medical Director for several emergency departments in Southern Florida as well EMS Medical Director for the City of Pembroke Park, FL.

PharmaTher Files FDA Pre-IND Meeting Request and Briefing Package For KETABET™ To Treat Depression

Retrieved on: 
Tuesday, June 15, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Sedatives, Analgesics, Ketones, Homocystinuria, Psychedelic drug, Ketamine

KETABET has the potential to receive FDA approval under the 505(b)(2) regulatory pathway and Fast Track designation by the FDA for treatment in patients with major depressive disorder.

Key Points: 
  • KETABET has the potential to receive FDA approval under the 505(b)(2) regulatory pathway and Fast Track designation by the FDA for treatment in patients with major depressive disorder.
  • storage, distribution and self-administration) of these psychedelics that currently must be taken orally, inhaled, injected and intravenously.
  • Betaine anhydrous (CYSTADANE) was approved by the FDA in 1996 to treat homocystinuria to decrease elevated homocysteine blood concentrations.
  • PharmaTher is currently conducting an FDA approved phase 2 clinical study with ketamine to treat Parkinsons disease and is developing a novel microneedle patch for the intradermal delivery of psychedelics.

FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study

Retrieved on: 
Monday, June 14, 2021
Branches of biology, Neurochemistry, GABAA receptor positive allosteric modulators, Gába, GABAA receptor, Allosteric modulator, gamma-Aminobutyric acid, Allosteric regulation

PPD, a major depressive disorder that is under diagnosed in US, impacts approximately 1 in 7 women after giving birth.

Key Points: 
  • PPD, a major depressive disorder that is under diagnosed in US, impacts approximately 1 in 7 women after giving birth.
  • The active moiety in LPCN 1154 is an endogenous positive allosteric modulator of -aminobutyric acid ("GABAA") receptor.
  • Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154, and LPCN 1107.
  • LPCN 1154 is an oral neuro-steroid targeted for the treatment of post-partum depression.

Ketamine One Appoints Loreto Grimaldi to Board of Directors

Retrieved on: 
Monday, June 14, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Arylcyclohexylamines, Nicotinic antagonists, General anesthetics, Sedatives, Ketamine, Loreto, Baja California Sur, Olney's lesions, Loreto

Mr. Grimaldi brings over 25 years of corporate, transactional and governance experience to Ketamine One.

Key Points: 
  • Mr. Grimaldi brings over 25 years of corporate, transactional and governance experience to Ketamine One.
  • On behalf of the Company, I extend a warm welcome Loreto as the newest member of Ketamine Ones Board of Directors, said Rob Meister, Chief Executive Officer of Ketamine One.
  • Loreto is also the co-founder of Untether Capital Inc. dba Fleets Coffee, which is a disruptive food technology platform.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol

Retrieved on: 
Monday, June 14, 2021
Drugs, Health care, Neurochemistry, Serotonin-norepinephrine reuptake inhibitors, Nicotinic antagonists, Food and Drug Administration, Tramadol, New Drug Application

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that it has received a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) seeking approval for IV tramadol.

Key Points: 
  • NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that it has received a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) seeking approval for IV tramadol.
  • The FDA did not identify any Chemistry, Manufacturing and Controls (CMC) issues in this CRL.
  • Avenue disagrees with the FDA's interpretation of the data in the NDA and intends to continue to pursue regulatory approval for IV tramadol.
  • Avenue Therapeutics is a specialty pharmaceutical company whose mission is to develop IV tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the U.S. Avenue is headquartered in New York City and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO).

ESO Publishes Peer-Reviewed Paper On Prehospital Ketamine Use At A National Level

Retrieved on: 
Friday, June 11, 2021
Research, Technology, Hospitals, Software, Practice Management, Other Health, Pharmaceutical, Health, Data management, Science, Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Arylcyclohexylamines, Ketones, Nicotinic antagonists, Sedatives, Ketamine, European Southern Observatory, ESO, the Ketamine Research, ESO, THE KETAMINE RESEARCH, ESO

The study uses data from the ESO Data Collaborative, one of the largest prehospital research databases in the country.

Key Points: 
  • The study uses data from the ESO Data Collaborative, one of the largest prehospital research databases in the country.
  • View the full release here: https://www.businesswire.com/news/home/20210611005060/en/
    The ketamine conversation has reached a national, mainstream audience, said Dr. Brent Myers, Chief Medical Officer for ESO.
  • EMS Ketamine Administrations: Based on data from the ESO Data Collaborative, EMS administered ketamine to 11,291 patients from January 1, 2019-December 31, 2019.
  • ESO (ESO Solutions, Inc.) is dedicated to improving community health and safety through the power of data.

Clean Remedies Highlights Two Energy Boosting CBD Infused Products

Retrieved on: 
Friday, June 11, 2021
Psychoactive drugs, Drugs, Neurochemistry, Stimulants, Caffeine, Mutagens, Gummy candy, Nicotine

Clean Remedies has Organic Sour CBD Gummies and CBD Pouches .

Key Points: 
  • Clean Remedies has Organic Sour CBD Gummies and CBD Pouches .
  • For those looking for an oral fixation without the use of tobacco or nicotine products, Clean Remedies CBD Pouches can be a friendly alternative.
  • Both items in Clean Remedies' energy-boost CBD product line can help people reinvigorate their daily routine.
  • Using all-natural ingredients, CBD Power Pouches and CBD Sour Gummies can help you get through the day without that caffeine burnout.